| abstract |
Prodrugs of COX-2 inhibitors of formula (I) have been described as useful agents in the treatment of inflammation and inflammation-related disorders; wherein A is a partially unsaturated heterocyclyl, heteroaryl, cycloalkenyl and aryl selected ring substituent and can be optionally substituted as described in the specification; R1 is selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl and can be optionally substituted as set forth in the specification; R2 is selected from hydrido and alkoxycarbonylalkyl; and R3 is selected from alkyl, carboxyalkyl, acyl, alkoxycarbonyl, heteroarylcarbonyl, alkoxycarbonylalkylbonyl, alkoxycarbonylcarbonyl, amino acid residue and alkylcarbomylaminoalkylcarbonyl; however, water A must not be tetrazolium or pyridinium; and furthermore, water should not be indanon when R3 is alkyl or carboxyalkyl; and their pharmaceutically acceptable salts are disclosed. |